Edwards SAPIEN 3 Transcatheter Heart Valve Receives Approval In China

Xenter, Inc. Appoints 4 Industry Leaders to Board of Directors; Closes $12M Series A

Xenter’s first product, which the company will announce shortly, is a medical device that not only combines the function of multiple existing devices but will also revolutionize the field of interventional medicine by producing valuable Physical Intelligence™ data and enabling advanced Artificial Intelligence solutions, leading to improved patient outcomes while reducing the cost, complexity and invasiveness of cardiac procedures.

Indivumed Partners with Oslo University Hospital to Advance Cancer Research

By scanning high-resolution images of haematoxylin and eosin-stained tumor section slides for all IndivuType cases, Indivumed will be able to leverage an entirely new dimension of data in the coming months.

Harold Hill Joins NeuX Technologies as Director of Corporate Accounts

Harold Hill is a retired Special Forces Medic, serving 26 years, and led the medical department for a Special Missions Unit within the United States Special Operations Command

Edwards Lifesciences Corporation today announced that it has received Chinese regulatory approval for the Edwards SAPIEN 3 transcatheter heart valve for the treatment of patients suffering from severe, symptomatic aortic stenosis (AS) at high risk for or unable to undergo open-heart surgery.

“Now, in China, patients diagnosed with severe AS have the option of a shorter procedure with excellent clinical outcomes, including a more rapid recovery than open-heart surgery,” said Prof. Junbo Ge, MD, academician of the Chinese Academy of Sciences, chairman, Shanghai Institute of Cardiovascular Diseases and Director, Department of Cardiology, Zhongshan Hospital, Fudan University.

  • The SAPIEN 3 valve builds on Edwards’ decades of experience in the development of tissue heart valves, and the proven benefits of the Edwards SAPIEN transcatheter heart valves.
  • The SAPIEN TAVR valves are the most widely studied transcatheter valves, with more than 30,000 patients treated in clinical trials and registries in over 65 countries around the world.
  • The approval for high-risk and extreme-risk patients in China was supported by the China SAPIEN 3 study, which complements a highly robust set of clinical outcomes from three randomized controlled PARTNER studies, along with excellent real-world results.

“This approval marks a major milestone for Chinese physicians and their patients living with severe AS in need of alternatives to open-heart surgery,” said Larry L. Wood, Edwards’ corporate vice president, transcatheter aortic valve replacement. “Edwards is proud to introduce this technology, which has demonstrated successful outcomes for patients worldwide, into China. We look forward to partnering with hospitals throughout China to introduce this therapy through our comprehensive, globally proven training program.”

The valve, available in 20mm, 23mm, 26mm and 29mm sizes, is approved by the National Medical Products Administration for treating high-risk patients in China. To date, more than 650,000 patients around the world have benefitted from TAVR.



Subscribe to Medical Device News Magazine

Related Articles